Arrowhead Pharmaceuticals reported early-phase signals from its RNAi obesity programs, including ARO‑INHBE dosed in combination with Lilly’s tirzepatide (Zepbound). Interim results indicated larger fat loss and liver‑fat reductions for the combo arm versus tirzepatide alone, prompting the company to advance programs into Phase 2 testing. Data presented and company releases highlighted visceral fat reductions and liver-fat improvements as key secondary measures. Arrowhead characterized the findings as proof-of-concept that RNAi-mediated targets can enhance GLP‑1/GIP agonist responses, while the industry noted the results are preliminary and require larger cohorts to confirm durability and safety.